Investor presentation

NASDAQ: STXS

Exhibit 99.1

Forward-Looking Statements

During the course of this presentation, the Company may make projections and other forward-

looking statements regarding future events or the future financial performance of the Company,

including without limitation, statements regarding future operating results, growth opportunities

and other statements that refer to Stereotaxis’ plans, prospects, expectations, strategies,

intentions and beliefs. These statements are subject to many risks and uncertainties that could

cause actual results to differ materially from expectations.

For a detailed discussion of risks and uncertainties that affect the Company’s business and

qualify the forward-looking statements made in this presentation, we refer you to the Company’s

recent public filings filed with the SEC, specifically the Form 10-K for the fiscal year ended

December 31, 2009.

The Company’s projections and forward-looking statements are based on factors that are subject

to change and therefore these statements speak only as of the date they are given. The

Company assumes no obligation to update any projections or forward-looking statements.

In addition, regarding orders and backlog, there can be no assurance that the Company will

recognize revenue related to its purchase orders and other commitments in any particular period,

or at all, because some of these purchase orders and other commitments are subject to

contingencies that are outside of our control. These orders and commitments may be revised,

modified, or canceled either by their express terms, as a result of negotiations, or by project

changes or delays.

Investment Considerations

Two innovative technology platforms:

Niobe

Magnetic Navigation System

Odyssey

™

Enterprise Solutions

Substantial IP portfolio

Large, fast growing (+20%) cardiology ablation market

Poised for continued growth in electrophysiology (EP)

Expansion into new markets

New geographic opportunities

Broad clinical applications beyond EP

Multi-dimensional strategy to accelerate growth

Niobe

Magnetic Navigation System

Magnet-guided catheter distal tip provides precise remote control of therapeutic

devices.

Niobe Provides Precision and Safety

Precise control of catheter distal tip provides:

Effective lesion creation through

constant contact

Exceptional mapping capability

Exemplary safety

Proven in all chambers of the heart

Manual

Niobe

Physician

Efficacy

Safety

Efficiency

In procedure room exposed to fluoroscopy

Physician:

Significant X-ray exposure

Patient: Major event rate ~2.8%

Higher variability in procedure times

In control room outside fluoroscopy field

Clearly better in several applications

VT, pediatrics, congenital heart diseases

Other applications comparable to manual

Physician:

Almost no X-ray exposure

Patient: Major event rate ~0.1%

Standardized process drives tighter

distribution around procedure times

High re-do rates

Niobe’s Advantages

Atrial

Fibrillation

30 Publications

100%

acute

success

Improved

chronic

outcomes

Pediatric Arrhythmia

5 publications

93%

acute

success

Low fluoro, no complications

Congenital Heart

6 publications

90%

success

rate

“As easy as normal adults”

Ventricular Tachycardia

13 publications

100%

acute

success

85%

freedom

year

Radiation Reduction

Patients –

67%

Physicians –

90%

1. Haghjoo, JCE 2009. 2. Latcu, Arch Cardiovasc

Dis

2009. 3. Schwagten, PACE 2009. 4. DiBiase, JCE 2009.

5. Augello, Heart Rhythm 2009. 6. Schwagten, PACE 2009. 7. Haghjoo, JCE 2009. 8. Dibiase, Heart Rhythm 2009.

Strong Clinical Validation

More than 150 peer-reviewed publications highlight Niobe’s

value

Major Advantages in Ventricular Tachycardia Ablation

97%

24%

170

81%

28%

228

100

150

200

250

Acute Success (%)

Recurrence (%)

Case Time (min)

Fluoro Time (min)

RF Apps

STXS

Manual

= 0.03

< 0.01

< 0.001

•

VT is an abnormally fast heart rhythm that originates from one of the ventricles and can

lead to potentially life threatening complications.

•

64 consecutive VT ablation patients

–

37 Niobe; 27 manual procedures

–

Idiopathic & Scar-Related

•

No complications in Niobe

group

•

1 tamponade/death in manual group

•

Conclusion:

Niobe

offers

“major

clinical

cost

advantages

for

ablation”

Schwagten, et al. Eur

Heart J 2010, 31 (Supp):932.

Global EP Market is Large and Growing

Source: Millennium Research Group (2009); Stereotaxis internal analysis

EP Procedures

Routine

Other

Total

Complex

Prevalence

Annual

Procedures

Annual

Growth

>20M

>10M

>3M

>5M

>18M

170K

100K

30K

40K

170K

<10%

25%

15%

20%

Stereotaxis

focused on

complex

ablation,

high-growth

segments

Niobe

Market Adoption & Procedure Growth

30,000 + procedures

Cumulative Procedures

Growing Worldwide Penetration

141 Systems Installed

60% US -

40% OUS

Canada -

United States -

Europe -

Saudi Arabia -

Russia -

China -

Korea -

Japan -

Singapore -

Taiwan -

Australia -

Odyssey Enterprise

Solutions

Odyssey

Vision

Integrates and centralizes all EP lab related information to significantly enhance

physicians’

efficiency

The Odyssey Product Line

140 Niobe

Labs

CONNECT

CINEMA

VISION

Efficiently integrate

data and control

during procedures

Standardize all labs

to increase staff

effectiveness

Drive world-class

practices by capturing,

compressing and

recording data for

storage and networking

NIOBE

Accelerate clinical

education by playing

back synchronized lab

data

Drive quality of

patient care by

connecting clinical

experts

Build market exposure

through live web events

showcasing clinical

capabilities

Enhance clinical

capabilities with a

robotic suite

15,000 Interventional

Standard Labs

ODYSSEY

Business Model

Capital Revenue

Recurring Revenue

Niobe

Odyssey

Workstation

Odyssey

Cinema

•

141 Niobe

systems installed

•

2,500 EP labs worldwide

•

20+% growth; ~60% margin

•

25% growth (YTD 2010 vs. 2009)

•

80% margin

Capital Driven

•

Technical service

•

Software license

Niobe

Utilization

•

Stereotaxis

disposables

•

Royalty from J&J BWI

27% growth (2009 vs. 2008); 65+% margin

Strategies to Accelerate Growth

$0.0

$4.0

$8.0

$12.0

$16.0

2008

2009

2010

$11.2

$8.8

$7.2

$7.3

$5.0

$10.2

$12.4

$6.3

$11.2

$7.7

New Orders to Backlog

Revenue Momentum

Recurring Revenue

$ millions

$10

$12

$14

$16

2008

2009

2010

$7.0

$11.1

$10.6

$10.7

$12.6

$15.0

$10.6

$13.3

$12.1

$14.1

$ millions

Stereotaxis

Financial Update

$0.0

$4.0

$8.0

$12.0

2008

2009

2010

Total Inventory

-$20.0

-$15.0

-$10.0

-$5.0

$0.0

$5.0

2008

2009

2010

Cash Flow (Burn)

$0.0

$5.0

$10.0

$15.0

$20.0

$25.0

2008

2009

2010

Operating Expenses

55.0%

60.0%

65.0%

70.0%

75.0%

2008

2009

2010

Gross Margin Percentage

$ millions

65.5%

68.9%

72.5%

60.8%

63.1%

65.5%

67.8%

67.6%

67.3%

$17.8

$14.8

$14.0

$18.7

$14.6

$16.1

$13.3

$14.6

$15.3

-$12.6

-$11.4

-$6.4

-$7.6

-$5.8

-$5.6

-$3.5

-$4.5

-$2.9

$10.5

$8.1

$4.9

$9.6

$7.5

$8.4

$7.0

$8.1

$4.4

67.2%

$15.8

$4.3

-$7.9

Stereotaxis

Financial Update

Liquidity

$3.0

$1.3

$3.6

$10

2010

Operating Cash Flow Ex A/R

BWI Debt

Accounts Receivable

Q2 2010 Cash Burn Analysis

$ Millions

$7.9

$ Millions

* Cash burn includes repayment of Biosense Webster advance.

Investment Considerations

Two innovative technology platforms:

Niobe

Magnetic Navigation System

Odyssey

™

Enterprise Solutions

Substantial IP portfolio

Large, fast growing (+20%) cardiology ablation market

Poised for continued growth in electrophysiology (EP)

Expansion into new markets

New geographic opportunities

Broad clinical applications beyond EP

Multi-dimensional strategy to accelerate growth

Q & A